[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-smoking\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-smoking":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,69,95,125,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125",false,"NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","ALL","14 Years","17 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Cannabis Use","Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[55,38,46],"Cannabis","RECRUITING","2026-06-18",{"date":59,"type":60},"2026-06-22","ACTUAL",{"date":62,"type":60},"2026-06-15",{"date":64,"type":22},"2030-05-01",{"name":66,"class":67},"Indiana University","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":68},"100623577","using-novel-behavioral-economic-measures-to-characterize-dual-marijuana-and-tobacco-use-in-young-adults-100623577","NCT07398443","Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults","MATEY","Inclusion Criteria:\n\n1. Males\u002Ffemales who are 18 to 25 years of age\n2. Young adults who currently smoke commercial tobacco cigarettes (≥1x weekly in the past 30 days and for the past six months)\n3. Young adults who currently smoke marijuana (≥4 times in past 30 days and at least weekly on average for the last six months)\n4. Participants must report purchasing their own tobacco and marijuana at least once in the past 6 months\n5. Participants must speak, comprehend, and read English.\n\nExclusion Criteria:\n\n1. Intention to quit marijuana or tobacco use in the next 30 days\n2. Self-reported illicit drug or heavy episodic alcohol use on \\>20 days in the past month (excluding marijuana)\n3. Individuals who are pregnant or breastfeeding\n4. Positive saliva test for recent THC use\n5. Breath alcohol level above 0 at any session.\n6. Participants who exclusively roll their own tobacco cigarettes",true,"18 Years","25 Years",{"count":80,"type":22},120,[25],"The multi session experimental study aims to determine dual use patterns of marijuana and tobacco by assessing the impact of price and availability of marijuana and tobacco using a cross price elasticity of demand task. The study will recruit 120 non-treatment seeking emerging young adults (18-25 years) who smoke marijuana and tobacco.",[84,33,85],"Behavioral Economics","Tobacco Smoking","2026-03-02",{"date":88,"type":60},"2026-03-04",{"date":90,"type":60},"2026-02-17",{"date":92,"type":22},"2028-11-30",{"name":94,"class":67},"Brown University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":76,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":68},"100516043","phase-2-understanding-the-clinical-pharmacology-of-marijuana-tobacco-co-administration-100516043","NCT05999383","Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration","CANNIC","Inclusion Criteria:\n\n* Heart rate \\\u003C 105 beats per minute (BPM)\\*\n* Systolic Blood Pressure \\\u003C 160 and \\> 90\\*\n* Diastolic Blood Pressure \\\u003C 100 and \\> 50\\*\n\n  \\*Considered out of range if both machine and manual readings are above\u002Fbelow these thresholds.\n* Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)\n* Current regular user of cannabis who smokes or vapes cannabis or THC extracts at least three days a week for the past 3 months or more\n* Test positive for D-9-tetrahydrocannabinol (THC) at screening and self-report of cannabis use\n* Current user of inhaled forms of tobacco\u002Fnicotine (cigarette, cigars, e-cigarettes) who use the product daily for the past 3 months or more\n* Saliva cotinine ≥ 30 ng\u002FmL\n\nExclusion Criteria:\n\n* Unstable medical conditions:\n\n  * Heart disease\n  * Seizures\n  * Cancer\n  * Thyroid disease (okay if controlled with medication)\n  * Diabetes\n  * Hepatitis B or C or Liver disease\n  * Glaucoma\n  * Kidney disease or urinary retention\n  * An ulcer in the past year\n  * Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)\n* Hypertension if uncontrolled (meaning participant has a diagnosis, but they are not taking medication\u002Funder treatment (e.g., diet or exercise plan)\n* Drug\u002FAlcohol Dependence\n\n  * Alcohol or illicit drug dependence within the past 12 months (currently in treatment) with the exception of those who recently completed an alcohol\u002Fdrug treatment program\n  * Positive toxicology test at the screening visit (THC \\& prescribed medications okay)\n  * Opioid replacement therapy (including methadone, buprenorphine, or other)\n* Psychiatric conditions\n\n  * Current or past schizophrenia, and\u002For current or past bipolar disorder\n  * Major depression, current or within the past year\n  * Major personality disorder\n  * Participants with current or past minor or moderate depression and\u002For anxiety disorders will be reviewed by the PI \\[study physician\\] and considered for inclusion\n  * History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's \\[study physician's\\] approval\n* Current regular use of any psychiatric medications with the exception of Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate\n* Congenital or acquired immunodeficiency disorders (i.e. HIV, congenital immune deficiency syndrome, chronic diseases)\n* Other disorders (i.e. ICU, malnutrition, immunosuppressive therapy)\n* Traumatic brain injury\n* Recent onset or change (worsening) in cough, fever and\u002For abdominal symptoms (vomiting or pain) in the past two weeks\n* Medications\n\n  * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs)\n  * Concurrent use of nicotine-containing medications\n  * Any stimulant medications (ex. Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment\n* Other\u002FMisc. Chronic Health Problems\n\n  * Oral thrush\n  * Fainting\n  * Other \"life threatening illnesses\" as per study physician's discretion\n* Pregnancy\n\n  * Pregnancy (self-reported and urine pregnancy test)\n  * Breastfeeding (determined by self-report)\n* Concurrent participation in another clinical trial\n* Inability to communicate in English\n* History of marijuana-induced psychosis or paranoia after smoking marijuana\n* Scoring a 7 or higher on the Severity of Dependence Scale (SDS) for cannabis use\n* Planning to quit smoking or vaping within the next 60 days\n* Planning to quit cannabis use within the next 60 days\n* Uncomfortable with getting blood drawn\n* Willingness to abstain from tobacco smoking and all combustible products for 13 hours before admission\n* Willingness to abstain from smoking\u002Fingestion of cannabis 13 hours before\n* Willingness to abstain from nicotine products 13 hours before each admission","21 Years","65 Years",{"count":105,"type":22},48,[107],"PHASE2","This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.",[110,55,28,33,111,112],"THC","Tobacco Use","Vaping",[110,55,38,114,115],"Nicotine","Vape","2026-01-05",{"date":118,"type":60},"2026-01-07",{"date":120,"type":60},"2025-07-01",{"date":122,"type":22},"2028-02-01",{"name":124,"class":67},"University of California, San Francisco",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":76,"sex":17,"minAge":77,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":68},"100355555","longitudinal-study-of-xenon-129-mri-imaging-effects-of-cannabis-smoking-100355555","NCT03909477","Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking","Longitudinal Study of Xenon-129 MRI Imaging of Effects of Cannabis Smoking on Lung Structure and Function","Inclusion Criteria:\n\n* Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature\n* Provision of written, informed consent prior to any study specific procedures\n* Males and females aged 18-85\n* Current or former cannabis smoker (medicinal or recreational) with or without concurrent tobacco smoking history\n* Participant is able to perform reproducible pulmonary function testing (i.e. the 3 best acceptable spirograms have Forced Expiratory Volume in 1 second (FEV1) values that do not vary more than 150 millilitres)\n* Participant is able to perform a breathhold for 16s\n* FEV1 \\> 25% predicted\n* Forced Vital Capacity (FVC) \\> 25% predicted and \\>0.5 litres\n\nExclusion Criteria:\n\n* Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand written material\n* Participant is medically unstable in the opinion of the Principal Investigator\n* Participant has a daytime room air oxygen saturation \\\u003C90% while lying supine\n* Participant is unable to perform spirometry or plethysmography maneuvers\n* Patient is pregnant at time of enrolment\n* In the opinion of the investigator, patient suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia\n* Patient has implanted mechanically, electrically or magnetically activated device or any metal in their body, which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) - at the discretion of the MRI Technologist.","85 Years",{"count":134,"type":22},200,"OBSERVATIONAL","This is a longitudinal study of the long-term health impact of cannabis smoking on the lungs. Participants will be followed over a period of 3 years, and impacts of cannabis smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.",[28,33,41,138],"Marijuana Usage","2025-08-11",{"date":141,"type":60},"2025-08-15",{"date":143,"type":60},"2022-06-01",{"date":145,"type":22},"2030-12-01",{"name":147,"class":67},"Western University, Canada",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":76,"sex":17,"minAge":77,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":68},"100245963","chronic-cannabis-smoking-oxidative-stress-and-the-pulmonary-innate-immune-response-100245963","NCT02480283","Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response","Inclusion Criteria:\n\nINCLUSION CRITERIA for CANNABIS USING patient: Subjects will be eligible if they meet ALL of the following criteria:\n\n1. Daily or near daily cannabis use (inhaled via joint\u002Fcigarette or pipe) equivalent to AT LEAST 20 \"joint years\" (number of joints\u002Fcigarettes per day multiplied by number of years during which cannabis was smoked) by self-report and validated through urine drug screen.\n2. Never or limited exposure to inhaled tobacco products (equivalent to LESS THAN one \"pack year\" in a lifetime) by selfreport and validated through negative urine cotinine screen.\n3. Capacity to answer screening questions and provide informed consent at time of interview, along with contact information\n\nINCLUSION CRITERIA for CONTROL patient: Subjects will be eligible if they meet all of the following:\n\n1. No cannabis use ever by self-report, and validated through urine drug screen.\n2. Never users of tobacco\u002Fcigarettes\n3. Capacity to answer screening questions and provide informed consent at time of interview, along with contact information.\n\nExclusion Criteria:\n\nEXCLUSION CRITERIA for CANNABIS USING patient: Subjects will be ineligible if they meet ANY of the following criteria:\n\n1. LESS THAN near daily cannabis use (inhaled via joint\u002Fcigarette or pipe) equivalent to LESS THAN 20 \"joint years\" (number of joints\u002Fcigarettes per day multiplied by number of years during which cannabis was smoked) or a negative urine drug screen (for cannabis)\n2. Inhaled tobacco product exposure EXCEEDING one \"pack year\" or a positive urine cotinine screen\n3. Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.\n4. Prior medical history of liver disease: cirrhosis, total bilirubin \\> 2.0 mg\u002FdL or albumin \\\u003C3\n5. Prior medical history of myocardial infarction or congestive heart failure\n6. Prior medical history of end-stage renal disease or serum creatinine \\>3 mg\u002FdL\n7. Prior history of or current use of illicit drug use defined as a positive toxicology screen for opiates or cocaine\n8. Prior history of diabetes mellitus\n9. Prior history of chronic obstructive pulmonary disease (COPD) or asthma that is not clinically controlled (have not required systemic corticosteroids in the past month)\n10. Prior history of HIV, not controlled or on medication\n11. Peripheral white blood cell count of less than 3000\n12. Acute worsening (\\\u003C7 days) in respiratory symptoms (such as change in cough frequency or sputum production, fever, dyspnea, abnormal chest radiograph), or room air pulse oximetry of \\\u003C 92% at rest or spirometry of \\\u003C 50% predicted for FEV1 and FVC\n13. Use of systemic antibiotics for any reason in the past month (4 weeks)\n14. Failure of a subject or the subject's substance abuse counselor to provide assent\n15. Nutritional risk index of less than 95\n16. Age \\\u003C 21 or \\> 55 (using an age of 55 limits the likelihood of comorbid conditions that may increase the risk of adverse events with bronchoscopy)\n17. Pregnancy\n18. Decisionally challenged\n19. Prisoners.\n\nEXCLUSION CRITERIA for CONTROL patient: Subjects will be ineligible to participate if they meet ANY of the following criteria:\n\n1. History of inhaled cannabis exposure EXCEEDING one \"joint year\" or positive urine toxicology screen (for cannabis)\n2. History of inhaled tobacco product exposure EXCEEDING one \"pack year\" or a positive urine cotinine screen\n3. Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.\n4. Prior medical history of liver disease: cirrhosis, total bilirubin \\> 2.0 mg\u002FdL or albumin \\\u003C3\n5. Prior medical history of myocardial infarction or congestive heart failure\n6. Prior medical history of end-stage renal disease or serum creatinine \\>3 mg\u002FdL\n7. Prior history of or current use of illicit drug use defined as a positive toxicology screen for opiates or cocaine\n8. Prior history of diabetes mellitus\n9. Prior history of chronic obstructive pulmonary disease (COPD) or asthma that is not clinically controlled (have not required systemic corticosteroids in the past month)\n10. Prior history of HIV, not controlled or on medication\n11. Peripheral white blood cell count of less than 3000\n12. Acute worsening (\\\u003C7 days) in respiratory symptoms (such as change in cough frequency or sputum production, fever, dyspnea, abnormal chest radiograph), or room air pulse oximetry of \\\u003C 92% at rest or spirometry of \\\u003C 50% predicted for FEV1 and FVC\n13. Use of systemic antibiotics in the past month (4 weeks)\n14. Failure of a subject or the subject's substance abuse counselor to provide assent\n15. Nutritional risk index of less than 95\n16. Age \\\u003C 21 or \\> 55\n17. Pregnancy\n18. Decisionally challenged\n19. Prisoners.","55 Years",{"count":156,"type":22},100,"This study plans to evaluate the effects of chronic cannabis smoking on lung health by evaluating its effects on pulmonary health, lung physiology and alveolar macrophage function.",[33,159],"Oxidative Stress","2024-10-07",{"date":162,"type":60},"2024-10-10",{"date":164,"type":60},"2015-11-11",{"date":166,"type":22},"2027-07",{"name":168,"class":67},"University of Colorado, Denver"]